J&J results
This article was originally published in The Tan Sheet
Executive Summary
Worldwide consumer health sales grew 9.9% to $2 bil. in the third quarter, with U.S. sales up 4% to roughly $1 bil. and international sales up 16.8% to $1 bil., J&J reports in an Oct. 12 earnings call. The firm cited Neutrogena skin care products as well its wound care business as strong contributors. Domestic sales were affected by the divestiture of the Splenda business, while international results included a continued impact from the acquisition of Merck's stake in the firms' joint European nonprescription business (1"The Tan Sheet" April 26, 2004. p. 6). McNeil's sales growth of 13% was primarily attributable to international sales...
You may also be interested in...
J&J Buyout Of Merck Stake In Europe Was In The Works “For Some Time”
Retaining rights to future Rx-to-OTC switches and a substantial one-time cash infusion were the major drivers of Merck's decision to sell its 50% stake of an OTC venture in Europe to partner Johnson & Johnson
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.